Walker on Progress

Voyager Therapeutics is streamlining its pipeline, prioritizing new small molecule programs alongside promising advancements in gene therapy delivery, including a novel non-viral platform and a Phase 1/2 Alzheimer's trial.

A fresh influx of funding and promising clinical data fuels 4D Molecular Therapeutics' efforts to revolutionize treatment for age-related macular degeneration, diabetic macular edema and cystic fibrosis with innovative gene therapies.

Biotech firm Protara Therapeutics is making strides with a promising cell therapy for non-muscle invasive bladder cancer and a unique treatment for a critical nutrient deficiency in patients on long-term parenteral support, bolstering its financial outlook.

Israeli medtech firm Nurami Medical receives FDA clearance for its innovative dural repair graft, ArtiFascia®, and secures significant funding, positioning it for growth in the $2 billion+ global dural repair market.

Cabaletta Bio’s innovative CAR-T cell therapy for autoimmune diseases is demonstrating encouraging clinical results, but the biotech faces significant financial challenges that cast a shadow over its future.

Data anomalies in a key clinical trial have sent Jasper Therapeutics’ stock plummeting and forced a dramatic refocus of its pipeline. A deep dive into the challenges and potential path forward.

CRISPR Therapeutics is pushing beyond its approved therapies with promising data in Alpha-1 Antitrypsin Deficiency, cardiovascular disease, and thrombosis. A closer look at the science and strategy.

Facing a critical funding crunch, Bluejay Diagnostics is pushing forward with a rapid sepsis diagnostic test, hoping to disrupt a market ripe for innovation but crowded with competition. Can they deliver before time – and money – runs out?

ADC Therapeutics has bolstered its financial position with a $60M financing, allowing it to double down on commercializing ZYNLONTA and advancing key clinical trials, despite recent revenue headwinds. The company's strategic pivot signals a focus on maximizing its lead asset.

Wave Life Sciences is making strides in metabolic and rare disease treatment with its innovative RNA-based therapies, but faces a crowded field and increasing financial scrutiny as it charts its path to commercialization.

Galecto’s acquisition of Damora Therapeutics, backed by a significant funding round, signals a promising advancement in targeted therapies for Myeloproliferative Neoplasms driven by the CALR mutation. The deal highlights a novel biotech launchpad model.

Facing financial headwinds, Biofrontera Inc. has sold its Xepi antibiotic cream to Pelthos Therapeutics, streamlining operations to prioritize its core photodynamic therapy business and pursue a viable path to profitability.

Pelthos Therapeutics expands its dermatology portfolio with the acquisition of Xepi, aiming to combat rising antibiotic resistance in impetigo treatment. A strategic move backed by robust funding.

Laborie Medical Technologies is expanding its obstetrics portfolio with the acquisition of the JADA System, a key device for postpartum hemorrhage control, while Organon focuses on core pharmaceutical strengths. The deal aims to improve patient outcomes and address a critical need in maternal health.

Harbour BioMed and Evinova are joining forces to leverage artificial intelligence in drug R&D, aiming to slash timelines and costs in the increasingly competitive biopharmaceutical landscape. A deep dive into the partnership and its implications.

A small medical device firm is making a bold move into the lucrative bone regeneration market, partnering with an Italian biomaterials innovator. Will this gamble pay off, or will established players shut them out?

MediciNova’s MN-166 (ibudilast) has received a key industry award, highlighting its potential in treating ALS. This comes amidst growing challenges in neurological disease research and limited effective treatments.

Innovative packaging protects delicate therapies, unlocking potential for personalized medicine. Cryoport’s solution is poised to capitalize on the booming regenerative medicine market.

ALZpath’s pTau217 antibody is earning accolades and gaining traction in the diagnostics market, promising earlier, more accessible detection of Alzheimer’s disease – but what are the broader implications?

RenovoRx strengthens its pancreatic cancer program with a key advisory board appointment & promising data for its localized drug delivery system, potentially revolutionizing treatment.